Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Milnacipran HCl
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : 1315 Capital
Deal Size : Undisclosed
Deal Type : Financing
USpharma Ltd. Secures Growth Capital Investment by 1315 Capital
Details : The capital infusion will enable USpharma to accelerate the development and commercialization of its pipeline, including Milnacipran tablets reference product of Savella.
Product Name : Savella-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 30, 2025
Lead Product(s) : Milnacipran HCl
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : 1315 Capital
Deal Size : Undisclosed
Deal Type : Financing